Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Reduced RNA-binding protein HuD in pancreatic neuroendocrine tumors lowers p27Kip1 levels linked to poor prognosis.

Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, Ahn S, Kim YJ, Kim YS, Nam SW, Kulkarni RN, Lee KB, Lee EK, Kim W.

J Pathol. 2018 Jul 17. doi: 10.1002/path.5135. [Epub ahead of print]

PMID:
30014466
2.

Complex HuR function in pancreatic cancer cells.

Brody JR, Dixon DA.

Wiley Interdiscip Rev RNA. 2018 May;9(3):e1469. doi: 10.1002/wrna.1469. Epub 2018 Feb 16. Review.

3.

Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.

Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA.

Mol Cell Biol. 2018 Jan 16;38(3). pii: e00427-17. doi: 10.1128/MCB.00427-17. Print 2018 Feb 1.

4.

Adrenaline promotes epithelial-to-mesenchymal transition via HuR-TGFβ regulatory axis in pancreatic cancer cells and the implication in cancer prognosis.

Pu J, Zhang X, Luo H, Xu L, Lu X, Lu J.

Biochem Biophys Res Commun. 2017 Nov 25;493(3):1273-1279. doi: 10.1016/j.bbrc.2017.09.146. Epub 2017 Sep 28.

PMID:
28965949
5.

CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.

Yu S, Parameswaran N, Li M, Wang Y, Jackson MW, Liu H, Xin W, Zhou L.

Oncotarget. 2016 Dec 26;8(32):52432-52444. doi: 10.18632/oncotarget.14194. eCollection 2017 Aug 8.

6.

Depletion of Beta Cell Intranuclear Rodlets in Human Type II Diabetes.

Zhou YY, El Hallani S, Balaa F, Mohammad W, Gray DA, Woulfe J.

Endocr Pathol. 2017 Dec;28(4):282-286. doi: 10.1007/s12022-017-9499-y.

PMID:
28770422
7.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

PMID:
28687616
8.

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM.

Cancer Res. 2017 Aug 15;77(16):4460-4471. doi: 10.1158/0008-5472.CAN-17-0015. Epub 2017 Jun 26.

9.

CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.

Lal S, Cheung EC, Zarei M, Preet R, Chand SN, Mambelli-Lisboa NC, Romeo C, Stout MC, Londin E, Goetz A, Lowder CY, Nevler A, Yeo CJ, Campbell PM, Winter JM, Dixon DA, Brody JR.

Mol Cancer Res. 2017 Jun;15(6):696-707. doi: 10.1158/1541-7786.MCR-16-0361. Epub 2017 Feb 27.

10.

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.

Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR.

Ann Surg. 2018 Feb;267(2):364-369. doi: 10.1097/SLA.0000000000002088.

PMID:
27893535
11.

GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.

Zhou H, Telonis AG, Jing Y, Xia NL, Biederman L, Jimbo M, Blanco F, Londin E, Brody JR, Rigoutsos I.

Cell Death Dis. 2016 Jul 14;7:e2294. doi: 10.1038/cddis.2016.169.

12.

Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy.

Li L, Chen H, Gao Y, Wang YW, Zhang GQ, Pan SH, Ji L, Kong R, Wang G, Jia YH, Bai XW, Sun B.

Mol Cancer Ther. 2016 Sep;15(9):2232-43. doi: 10.1158/1535-7163.MCT-16-0008. Epub 2016 Jul 1.

13.

Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.

Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T.

J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):480-8. doi: 10.1002/jhbp.366. Epub 2016 Jun 23.

PMID:
27247050
14.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

15.

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.

Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR.

Int J Biol Sci. 2016 Jan 27;12(3):273-82. doi: 10.7150/ijbs.14951. eCollection 2016. Review.

16.

HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z.

World J Gastroenterol. 2015 Dec 14;21(46):13004-19. doi: 10.3748/wjg.v21.i46.13004.

17.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
18.

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.

Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J.

Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11.

19.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

20.

Alanyl-glutamine improves pancreatic β-cell function following ex vivo inflammatory challenge.

Cruzat VF, Keane KN, Scheinpflug AL, Cordeiro R, Soares MJ, Newsholme P.

J Endocrinol. 2015 Mar;224(3):261-71. doi: 10.1530/JOE-14-0677. Epub 2014 Dec 30.

Supplemental Content

Loading ...
Support Center